HR阳性HER2低表达晚期乳腺癌治疗研究进展:2024 ASCO会议乳腺癌研究热点解读  

Research Progress in Treatment of HR-Positive/HER 2-Low Advanced Breast Cancer:Interpretation of Breast Cancer Research Hotspots in 2024 ASCO

作　　者：马艺文 徐君南 孙涛[1] MA Yiwen;XU Junnan;SUN Tao(Department of Oncology,Cancer Hospital of Dalian University of Technology,Cancer Hospital of China Medical University,Liaoning Cancer Hospital and Institute,Shenyang 110042,China)

机构地区：[1]大连理工大学附属肿瘤医院,中国医科大学附属肿瘤医院,辽宁省肿瘤医院肿瘤内科,沈阳110042

出　　处：《肿瘤防治研究》2025年第2期98-102,共5页Cancer Research on Prevention and Treatment

基　　金：沈阳市乳腺癌临床医学研究中心资助课题(2020-48-3-1);沈阳市科学技术计划公共卫生研发专项(22-321-31-04)。

摘　　要：HR阳性HER2低表达乳腺癌是一种新兴的、热点的治疗亚型,约占所有乳腺癌的53.7%。这类患者往往淋巴结转移率更高,新辅助化疗和传统抗HER2治疗的敏感性可能均较差,探索此类型患者的治疗策略是当前临床亟待解决的难题。HR阳性HER2低表达乳腺癌的治疗策略正在不断更新,包括CDK4/6抑制剂跨线治疗、新一代ADC药物如T-DXd等。随着未来HR阳性HER2低表达乳腺癌更多高级别循证依据的积累,研究数据将为精准诊疗提供更多实践支持,进一步改善HR阳性HER2低表达乳腺癌患者的预后。HR-positive HER2-low breast cancer is a new hotspot therapeutic subtype,accounting for approximately 53.7%of all breast cancers.Patients with this type of cancer tend to have a high rate of lymph node metastasis and poor sensitivity to neoadjuvant chemotherapy and conventional anti-HER2 therapy,and exploring therapeutic strategies for this subtype of patient is a current clinical challenge.Therapeutic strategies for HR-positive HER2-low breast cancer are constantly being updated,including CDK4/6 inhibitors across the lines of therapy,and next-generation antibody-drug conjugates such as T-DXd.With the accumulation of high-level evidence-based evidence for HR-positive HER2-low breast cancer in the future,the research data will provide more practical support for precise diagnosis and treatment,thereby improving the prognosis of patients with HR-positive HER2-low breast cancer.

关 键 词：HR阳性 HER2低表达 CDK4/6抑制剂 T-DXd 乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]